A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Glucosamine
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when Ponatinib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Glucosamine
Hypericin
The risk or severity of adverse effects can be increased when Ponatinib is combined with Hypericin.
Glucosamine
Acteoside
The risk or severity of adverse effects can be increased when Ponatinib is combined with Acteoside.
Glucosamine
Deoxyspergualin
The risk or severity of adverse effects can be increased when Ponatinib is combined with Deoxyspergualin.
Glucosamine
Doxifluridine
The risk or severity of adverse effects can be increased when Ponatinib is combined with Doxifluridine.
Glucosamine
Trofosfamide
The risk or severity of adverse effects can be increased when Ponatinib is combined with Trofosfamide.
Glucosamine
Cepeginterferon alfa-2B
The risk or severity of adverse effects can be increased when Ponatinib is combined with Cepeginterferon alfa-2B.
Glucosamine
Gusperimus
The risk or severity of adverse effects can be increased when Ponatinib is combined with Gusperimus.
Glucosamine
Mizoribine
The risk or severity of adverse effects can be increased when Ponatinib is combined with Mizoribine.
Glucosamine
Triptolide
The risk or severity of adverse effects can be increased when Ponatinib is combined with Triptolide.
Glucosamine
Ocrelizumab
The risk or severity of adverse effects can be increased when Ponatinib is combined with Ocrelizumab.
Glucosamine
Guselkumab
The risk or severity of adverse effects can be increased when Ponatinib is combined with Guselkumab.
Glucosamine
Baricitinib
The risk or severity of adverse effects can be increased when Ponatinib is combined with Baricitinib.
Glucosamine
Sirukumab
The risk or severity of adverse effects can be increased when Ponatinib is combined with Sirukumab.
Glucosamine
Brodalumab
The risk or severity of adverse effects can be increased when Ponatinib is combined with Brodalumab.
Glucosamine
Peficitinib
The risk or severity of adverse effects can be increased when Ponatinib is combined with Peficitinib.
Glucosamine
Voclosporin
The risk or severity of adverse effects can be increased when Ponatinib is combined with Voclosporin.
Glucosamine
Pirarubicin
The risk or severity of adverse effects can be increased when Ponatinib is combined with Pirarubicin.
Glucosamine
Ravulizumab
The risk or severity of adverse effects can be increased when Ponatinib is combined with Ravulizumab.
Glucosamine
Ixekizumab
The risk or severity of adverse effects can be increased when Ponatinib is combined with Ixekizumab.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3